Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ZymeTx, Inc. - ZMTX new biotech company -- Ignore unavailable to you. Want to Upgrade?

To: O. H. Rundell who wrote (39)	12/20/1997 5:17:00 PM
From: Wesley Jack	Read Replies (1) \| Respond to of 88

OKLAHOMA CITY, Dec. 18 /PRNewswire/ -- ZymeTx, Inc. (Nasdaq: ZMTX), a biotechnology company engaged in the discovery and development of products for diagnosis and treatment of viruses, announced today that its ZstatFlu(TM) kit, the only point-of-care (POC) test kit that enables medical professionals to diagnose both influenza A & B quickly, is now available nationwide. Since the company began commercial shipments early in December, it has already shipped over 10,000 kits. Its principal distributors have supplies of the kit in all their locations. "We are very pleased to achieve this milestone," said ZymeTx President and Chief Executive Officer Peter G. Livingston. "The initial 10,000 units represent the first of up to one million units we expect to ship this year. These shipments are particularly significant because they come at exactly the right time as the flu season in the United States is just getting underway. "We have been able to place quantities of the kits at all the locations of our distributors, McKesson General Medical and Bergen Brunswig, so medical professionals and managed care organizations across the nation now have ready access to ZstatFlu. Through our distributors' efforts and our own marketing force, we have made the care-givers aware that flu is a "wolf in sheep's clothing." Proper diagnosis, now possible at the point of care with ZstatFlu, can substantially reduce unnecessary antibiotic prescriptions and improve the quality of patient care. The initial response has been enthusiastic, and we will be shipping larger quantities in the coming weeks as influenza makes its annual appearance," Livingston said. ZymeTx noted the manufacturing and shipments of ZstatFlu continue to accelerate. The company expects to record its first commercial revenues in December. It expects shipments and revenues to peak in January and February to coincide with the height of the annual influenza season. As manufacturing volume increases, the efficiency of both manufacturing and distribution will improve correspondingly. "We are on our plan for the first year with ZstatFlu. I am optimistic that our financial performance in fiscal 1998 will mirror the success we've enjoyed in introducing the product to the marketplace," Livingston said. Note: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements regarding the company's results and trends in its business. These statements are based largely on management's expectations. The achievement of these results is subject to a number of risks and uncertainties beyond the company's control which may cause actual results to differ significantly. We refer to the company's fillings with the Securities and Exchange Commission, which include a more detailed description of these factors. ZymeTx, Inc. is a biotechnology company growing out of the research support of the Oklahoma Medical Research Foundation. The company, based in Oklahoma City, is engaged in the development of unique diagnostic and therapeutic products for the intervention and detection of viral diseases. The company's common shares are traded on the Nasdaq Stock Market under the symbol ZMTX. SOURCE ZymeTx, Inc. CO: ZymeTx, Inc. ST: Oklahoma IN: MTC SU: PDT 12/18/97 16:42 EST prnewswire.com